1
|
Ben-Meir E, Perrem L, Shaw M, Ratjen F, Grasemann H. SPLUNC1 as a biomarker of pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros 2024; 23:288-292. [PMID: 38413298 DOI: 10.1016/j.jcf.2024.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 02/14/2024] [Accepted: 02/19/2024] [Indexed: 02/29/2024]
Abstract
BACKGROUND Short palate, lung, and nasal epithelium clone 1 (SPLUNC1) is an innate defence protein that acts as an anti-microbial agent and regulates airway surface liquid volume through inhibition of the epithelial sodium channel (ENaC). SPLUNC1 levels were found to be reduced in airway secretions of adults with cystic fibrosis (CF). The potential of SPLUNC1 as a biomarker in children with CF is unknown. METHODS We quantified SPLUNC1, interleukin-8 (IL-8) and neutrophil elastase (NE) in sputum of CF children treated with either intravenous antibiotics or oral antibiotics for a pulmonary exacerbation (PEx)s, and in participants of a prospective cohort of CF children with preserved lung function on spirometry, followed over a period of two years. RESULTS Sputum SPLUNC1 levels were significantly lower before compared to after intravenous and oral antibiotic therapy for PEx. In the longitudinal cohort, SPLUNC1 levels were found to be decreased at PEx visits compared to both previous and subsequent stable visits. Higher SPLUNC1 levels at stable visits were associated with longer PEx-free time (hazard ratio 0.85, p = 0.04). SPLUNC1 at PEx visits did not correlate with IL-8 or NE levels in sputum or forced expiratory volume in one second (FEV1) but did correlate with the lung clearance index (LCI) (r=-0.53, p < 0.001). CONCLUSION SPLUNC1 demonstrates promising clinometric properties as a biomarker of PEx in children with CF.
Collapse
Affiliation(s)
- E Ben-Meir
- Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada; Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada
| | - L Perrem
- Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada; Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada
| | - M Shaw
- Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada; Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - F Ratjen
- Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada; Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada
| | - H Grasemann
- Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada; Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada.
| |
Collapse
|
2
|
Zikic A, Ratjen F, Shaw M, Tullis E, Waters V. 492 Effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)01182-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
3
|
Green N, Vu P, Skalland M, Schwarzenberg S, Freedman S, Pittman J, Ratjen F, Rosenfeld M, Lusman S. 224 Elexacaftor/tezacaftor/ivacaftor alters gastrointestinal symptoms and inflammation: Report of PROMISE Pediatric Gastrointestinal Study. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00914-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
4
|
Wainwright C, McColley S, McNally P, Powers M, Ratjen F, Rayment J, Retsch-Bogart G, Roesch E, Ahluwalia N, Chin A, Chu C, Lu M, Menon P, Moskowitz S, Waltz D, Weinstock T, Xuan F, Zelazoski L, Davies J. 163 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and at least one F508del alleles: 96-week interim results from an open-label extension study. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00854-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
5
|
Seidl E, Licht JC, Waters V, Ratjen F, Grasemann H. Profil leicht verdampfender organischer Substanzen in der Ausatemluft
von Kindern mit Mukoviszidose. Klinische Pädiatrie 2022. [DOI: 10.1055/s-0042-1754513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- E Seidl
- Hospital for Sick Children, Division of Respiratory Medicine, Toronto,
Canada
| | - J-C Licht
- Hospital for Sick Children, Division of Respiratory Medicine, Toronto,
Canada
- Research Institute, Hospital for Sick Children, Division of Respiratory
Medicine / Translational Medicine, Toronto, Canada
| | - V Waters
- Hospital for Sick Children, Division of Infectious Diseases, Toronto,
Canada
| | - F Ratjen
- Hospital for Sick Children, Division of Respiratory Medicine, Toronto,
Canada
- Research Institute, Hospital for Sick Children, Division of Respiratory
Medicine / Translational Medicine, Toronto, Canada
| | - H Grasemann
- Hospital for Sick Children, Division of Respiratory Medicine, Toronto,
Canada
- Research Institute, Hospital for Sick Children, Division of Respiratory
Medicine / Translational Medicine, Toronto, Canada
| |
Collapse
|
6
|
Ben-Meir E, Antounians L, Ratjen F, Zani A, Grasemann H. Extrazelluläre Vesikel im Sputum von Kindern mit zystischer
Fibrose und pulmonaler Exazerbation. Klinische Pädiatrie 2022. [DOI: 10.1055/s-0042-1754514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- E Ben-Meir
- Research Institute, The Hospital for Sick Children, Toronto,
Canada
| | - L Antounians
- Research Institute, The Hospital for Sick Children, Toronto,
Canada
| | - F Ratjen
- Research Institute, The Hospital for Sick Children, Toronto,
Canada
| | - A Zani
- Research Institute, The Hospital for Sick Children, Toronto,
Canada
| | - H Grasemann
- Research Institute, The Hospital for Sick Children, Toronto,
Canada
| |
Collapse
|
7
|
Dumas M, Jensen R, Au J, Munidasa S, Woods J, Robinson P, Santyr G, Ratjen F. 536: Evaluation of volume of trapped gas by multiple-breath washout and functional MRI in children with cystic fibrosis. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01959-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Munidasa S, Seethamraju R, Au J, Braganza S, Ratjen F, Santyr G, Zanette B, Couch M, Dumas M, Wee W. 161: Inter-visit reproducibility of free-breathing lung magnetic resonance imaging in cystic fibrosis. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01586-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Walkup L, Roach D, Santyr G, Fain S, Rock M, Mata J, Froh D, Stanojevic S, Ratjen F, Woods J. 537: 129Xe MRI is a repeatable measure of regional ventilation in children with stable CF. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01960-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Tiddens H, Chen Y, Andrinopoulou E, Davis S, Rosenfeld M, Stukovsky K, Ratjen F. 539: Effect of inhaled hypertonic saline on structural lung disease in preschool children with cystic fibrosis. The SHIP-CT study. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01962-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Gonska T, Keenan K, Au J, Dupuis A, Chilvers M, Bjornson C, Brusky J, Price A, Morgan L, Mateos-Corral D, Hughes D, Smith M, Iqbal S, Reisman J, van Wylick R, Derynck M, Ratjen F. WS06.2 Nutritional and pulmonary outcomes of cystic fibrosis screen-positive infants with an inconclusive diagnosis. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)00946-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Tiddens H, Chen Y, Davis S, Rosenfeld M, Ratjen F, Hinckley Stukovsky K, Andrinopoulou ER, Stick S. P058 The effect of hypertonic saline treatment in pre-schoolers with cystic fibrosis on lung structure as measured by chest computed tomography. SHIP-CT study. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01085-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
13
|
Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, VanDevanter DR, Davies JC, Lee T, Durmowicz AG, Ratjen F, Konstan MW, Pearson K, Bell SC, Clancy JP, Taylor-Cousar JL, De Boeck K, Donaldson SH, Downey DG, Flume PA, Drevinek P, Goss CH, Fajac I, Magaret AS, Quon BS, Singleton SM, VanDalfsen JM, Retsch-Bogart GZ. Building global development strategies for cf therapeutics during a transitional cftr modulator era. J Cyst Fibros 2020; 19:677-687. [PMID: 32522463 DOI: 10.1016/j.jcf.2020.05.011] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2020] [Revised: 05/18/2020] [Accepted: 05/27/2020] [Indexed: 12/30/2022]
Abstract
As CFTR modulator therapy transforms the landscape of cystic fibrosis (CF) care, its lack of uniform access across the globe combined with the shift towards a new standard of care creates unique challenges for the development of future CF therapies. The advancement of a full and promising CF therapeutics pipeline remains a necessary priority to ensure maximal clinical benefits for all people with CF. It is through collaboration across the global CF community that we can optimize the evaluation and approval process of new therapies. To this end, we must identify areas for which harmonization is lacking and for which efficiencies can be gained to promote ethical, feasible, and credible study designs amidst the changing CF care landscape. This article summarizes the counsel from core advisors across multiple international regions and clinical trial networks, developed during a one-day workshop in October 2019. The goal of the workshop was to identify, in consideration of the highly transitional era of CFTR modulator availability, the drug development areas for which global alignment is currently uncertain, and paths forward that will enable advancement of CF therapeutic development.
Collapse
Affiliation(s)
- N Mayer-Hamblett
- University of Washington, Seattle, WA; Seattle Children's Hospital, Seattle, WA.
| | - S van Koningsbruggen-Rietschel
- Cystic Fibrosis Center, Children's Hospital, University of Cologne; Faculty of Medicine and University Hospital Cologne, Cologne Germany
| | - D P Nichols
- University of Washington, Seattle, WA; Seattle Children's Hospital, Seattle, WA
| | - D R VanDevanter
- Case Western Reserve University School of Medicine, Cleveland, OH
| | - J C Davies
- National Heart & Lung Institute, Imperial College London, London, UK; Royal Brompton & Harefield NHS Foundation Trust, London, UK
| | - T Lee
- Leeds Regional Paediatric Cystic Fibrosis Centre, Leeds, UK
| | | | - F Ratjen
- University of Toronto, Toronto, Canada
| | - M W Konstan
- Case Western Reserve University School of Medicine, Cleveland, OH; Rainbow Babies and Children's Hospital, Cleveland, OH
| | - K Pearson
- Seattle Children's Hospital, Seattle, WA
| | - S C Bell
- Children's Health Research Centre, The University of Queensland, Brisbane, Australia
| | - J P Clancy
- Cystic Fibrosis Foundation, Bethesda, MD
| | | | | | - S H Donaldson
- University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - D G Downey
- Centre for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland
| | - P A Flume
- Medical University of South Carolina, Charleston, SC
| | - P Drevinek
- Charles University, Prague, Czechia, Motol University Hospital, Prague, Czechia
| | - C H Goss
- University of Washington, Seattle, WA; Seattle Children's Hospital, Seattle, WA
| | - I Fajac
- Université de Paris, Paris, France
| | - A S Magaret
- University of Washington, Seattle, WA; Seattle Children's Hospital, Seattle, WA
| | - B S Quon
- University of British Columbia, Vancouver, British Columbia
| | | | | | | |
Collapse
|
14
|
Hoppe J, Chilvers M, Ratjen F, McNamara J, Owen C, Tian S, Zahigian R, Cornell A, McColley S. WS19.2 Long-term safety of lumacaftor/ivacaftor therapy in persons with cystic fibrosis aged 2–5 years homozygous for the F508del-CFTR mutation (F/F). J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30265-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
15
|
Matenchuk BA, Tamana SK, Lou WY, Lefebvre DL, Sears MR, Becker AB, Azad MB, Moraes TJ, Turvey SE, Subbarao P, Kozyrskyj AL, Mandhane PJ, Subbarao P, Turvey S, Anand S, Azad M, Becker A, Befus A, Brauer M, Brook J, Chen E, Cyr M, Daley D, Dell S, Denburg J, Duan Q, Eiwegger T, Grasemann H, HayGlass K, Hegele R, Holness D, Hystad P, Kobor M, Kollmann T, Kozyrskyj A, Laprise C, Lou W, Macri J, Mandhane P, Miller G, Moraes T, Paré P, Ramsey C, Ratjen F, Sandford A, Scott J, Scott J, Sears M, Silverman F, Simons E, Takaro T, Tebbutt S, To T. Prenatal depression and birth mode sequentially mediate maternal education's influence on infant sleep duration. Sleep Med 2019; 59:24-32. [DOI: 10.1016/j.sleep.2019.01.015] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2018] [Revised: 11/15/2018] [Accepted: 01/10/2019] [Indexed: 10/27/2022]
|
16
|
Reix P, Klingel M, Davis S, Retsch-Bogart G, Stanojevic S, Ratjen F. WS07-3 Effect of cumulative bacterial infection on the Lung Clearance Index in preschool children with cystic fibrosis. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30156-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Gould MJ, Ratjen F, Gonska T. A184 PANCREATITIS IN A PREVIOUSLY PANCREATIC INSUFFICIENT PATIENT WITH CYSTIC FIBROSIS AFTER TREATMENT WITH LUMACAFTOR/IVACAFTOR COMBINATION THERAPY. J Can Assoc Gastroenterol 2019. [DOI: 10.1093/jcag/gwz006.183] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- M J Gould
- Hospital for Sick Children, Toronto, ON, Canada
| | - F Ratjen
- Hospital for Sick Children, Toronto, ON, Canada
| | - T Gonska
- Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, ON, Canada
| |
Collapse
|
18
|
Miliku K, Robertson B, Sharma AK, Subbarao P, Becker AB, Mandhane PJ, Turvey SE, Lefebvre DL, Sears MR, Bode L, Azad MB, Anand SS, Azad M, Becker AB, Befus AD, Brauer M, Brook JR, Chen E, Cyr M, Daley D, Dell SD, Denburg JA, Duan Q, Eiwegger T, Grasemann H, HayGlass K, Hegele RG, Holness DL, Hystad P, Kobor M, Kollman TR, Kozyrskyj AL, Laprise C, Lou WYW, Macri J, Miller G, Moraes TJ, Ramsey C, Ratjen F, Sandford A, Scott JA, Scott J, Silverman F, Simons E, Takaro T, Tebbutt S, To T. Human milk oligosaccharide profiles and food sensitization among infants in the CHILD Study. Allergy 2018; 73:2070-2073. [PMID: 29775217 DOI: 10.1111/all.13476] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Affiliation(s)
- K. Miliku
- Manitoba Developmental Origins of Chronic Diseases in Children Network (DEVOTION) Children's Hospital Research Institute of Manitoba Winnipeg MB Canada
- Department of Pediatrics and Child Health University of Manitoba Winnipeg MB Canada
- The Generation R Study Group Departments of Pediatrics and Epidemiology Erasmus University Medical Center Rotterdam Rotterdam The Netherlands
| | - B. Robertson
- Department of Pediatrics and Larsson‐Rosenquist Foundation Mother‐Milk‐Infant Center of Research Excellence University of California San Diego La Jolla CA USA
| | - A. K. Sharma
- George & Fay Yee Centre for Healthcare Innovation University of Manitoba Winnipeg MB Canada
| | - P. Subbarao
- Departments of Pediatrics & Physiology University of Toronto Toronto ON Canada
| | - A. B. Becker
- Manitoba Developmental Origins of Chronic Diseases in Children Network (DEVOTION) Children's Hospital Research Institute of Manitoba Winnipeg MB Canada
- Department of Pediatrics and Child Health University of Manitoba Winnipeg MB Canada
| | - P. J. Mandhane
- Department of Pediatrics University of Alberta Edmonton AB Canada
| | - S. E. Turvey
- Department of Pediatrics University of British Columbia Vancouver BC Canada
| | - D. L. Lefebvre
- Department of Medicine McMaster University Hamilton ON Canada
| | - M. R. Sears
- Department of Medicine McMaster University Hamilton ON Canada
| | - L. Bode
- Department of Pediatrics and Larsson‐Rosenquist Foundation Mother‐Milk‐Infant Center of Research Excellence University of California San Diego La Jolla CA USA
| | - M. B. Azad
- Manitoba Developmental Origins of Chronic Diseases in Children Network (DEVOTION) Children's Hospital Research Institute of Manitoba Winnipeg MB Canada
- Department of Pediatrics and Child Health University of Manitoba Winnipeg MB Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Taylor-Cousar J, Tullis E, Derichs N, Davies J, Nazareth D, Downey D, Rosenbluth D, Fajac I, Malfroot A, Saunders C, Short C, Jensen R, Solomon G, Vermeulen F, Willmann S, Saleh S, Langer S, Kaiser A, Hoffmann A, Rowe S, Ratjen F. P028 Riociguat for the treatment of adult Phe508del homozygous cystic fibrosis: efficacy data from the Phase II Rio-CF study. J Cyst Fibros 2018. [DOI: 10.1016/s1569-1993(18)30325-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
20
|
Ratjen F, Tian S, Marigowda G, Hug C, Huang X, Stanojevic S, Milla C, Robinson P, Waltz D, Davies J. WS13.4 Efficacy and safety of lumacaftor/ivacaftor (LUM/IVA) in patients (pts) aged 6–11 years (yrs) with cystic fibrosis (CF) homozygous for F508del-CFTR: a randomized placebo (PBO)-controlled phase 3 trial. J Cyst Fibros 2017. [DOI: 10.1016/s1569-1993(17)30234-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
21
|
Derichs N, Taylor-Cousar J, Tullis E, Davies J, Nazareth D, Downey D, Rosenbluth D, Fajac I, Malfroot A, Bakker M, Clancy J, Uluer A, Castellani C, Sermet-Gaudelus I, Ahrens R, Sutharsan S, Welte T, Gust T, Kaiser A, Hoffmann A, Ratjen F, Rowe S. EPS1.3 Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: study design and rationale for the Rio-CF study. J Cyst Fibros 2017. [DOI: 10.1016/s1569-1993(17)30276-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
22
|
Waters V, Stanojevic S, Klingel M, Chiang J, Sonneveld N, Kukkar R, Tullis E, Ratjen F. WS13.4 Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30082-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Grasemann H, Gonska T, Avolio J, Tullis E, Ratjen F. 144 Effect of treatment with ivacaftor on exhaled nitric oxide. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30321-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
24
|
McIlwaine M, Richmond M, Agnew J, Alarie N, Lands L, Chilvers M, Ratjen F. WS5.6 Cost-effectiveness of performing positive expiratory pressure versus high frequency chest wall oscillation. J Cyst Fibros 2014. [DOI: 10.1016/s1569-1993(14)60036-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
25
|
Schneiderman JE, Wilkes DL, Atenafu EG, Nguyen T, Wells GD, Alarie N, Tullis E, Lands LC, Coates AL, Corey M, Ratjen F. Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis. Eur Respir J 2013; 43:817-23. [DOI: 10.1183/09031936.00055513] [Citation(s) in RCA: 95] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
26
|
Alarie N, Agnew J, McIlwaine M, Ratjen F, Davidson G, Milner R, Lands L. WS14.1 Evaluation of physical activity using the habitual activity estimation scale (HAES) questionnaire in a multicenter study. J Cyst Fibros 2013. [DOI: 10.1016/s1569-1993(13)60083-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Ratjen F, Koker P, Geller D, Langellier-Cocteaux B, Maulf FL, Kattenbeck S, Moroni-Zentgraf P, Elborn J. 61 Tiotropium Respimat in cystic fibrosis: Efficacy and safety results of phase III randomized placebo-controlled trial. J Cyst Fibros 2013. [DOI: 10.1016/s1569-1993(13)60203-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
28
|
Geller D, Koker P, Elborn J, Le Maulf F, Kattenbeck S, Moroni-Zentgraf P, Ratjen F. 64 Tiotropium in cystic fibrosis: Pooled analysis of phase II and III randomized, controlled trials. J Cyst Fibros 2013. [DOI: 10.1016/s1569-1993(13)60206-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
29
|
Accurso F, Ratjen F, Altes T, Lubarsky B, Dong Q, Kang L, Davies J. 56 Effect of withdrawal of ivacaftor therapy on CFTR channel activity and lung function in patients with cystic fibrosis. J Cyst Fibros 2013. [DOI: 10.1016/s1569-1993(13)60198-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
30
|
McIlwaine M, Agnew J, Alarie N, Lands L, Ratjen F, Milner R, Davidson A. WS10.6 Canadian national airway clearance study: positive expiratory pressure mask versus high frequency chest wall oscillation. J Cyst Fibros 2012. [DOI: 10.1016/s1569-1993(12)60074-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
31
|
Davies J, Sheridan H, Lee PS, Song T, Stone A, Ratjen F. WS7.6 Effect of ivacaftor on lung function in subjects with CF who have the G551D-CFTR mutation and mild lung disease: a comparison of lung clearance index (LCI) vs. spirometry. J Cyst Fibros 2012. [DOI: 10.1016/s1569-1993(12)60049-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
32
|
Ratjen F, Rosenfeld M, Brumback L, Daniel S, Rowbotham R, Kronmal R, Davis S. WS22.1 Efficacy of hypertonic saline in infants and young children: the ISIS study. J Cyst Fibros 2012. [DOI: 10.1016/s1569-1993(12)60157-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
33
|
|
34
|
Eber E, Lødrup Carlsen KC, Ratjen F, Turner SW, Dankert-Roelse JE, Ross-Russell RI, Midulla F, Aurora P, Hedlin G. Paediatrics in Barcelona: highlights from the 2010 ERS Annual Congress. Eur Respir J 2011; 37:1514-21. [PMID: 21478214 DOI: 10.1183/09031936.00026311] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The aim of this update is to describe the paediatric highlights from the 2010 European Respiratory Society Annual Congress in Barcelona, Spain. Abstracts from the seven groups of the Paediatric Assembly (Respiratory physiology, Asthma and allergy, Cystic fibrosis, Respiratory infection and immunology, Neonatology and paediatric intensive care, Respiratory epidemiology and Bronchology) are presented in the context of the current literature.
Collapse
Affiliation(s)
- E Eber
- Department of Paediatrics, University Children's Hospital, Medical University of Graz, Auenbruggerplatz 34/2, 8036 Graz, Austria.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Hedlin G, Eber E, Aurora P, Lødrup Carlsen KC, Ratjen F, Dankert-Roelse JE, Ross-Russell RI, Turner S, Midulla F, Baraldi E, Bush A. Paediatric respiratory disease: past, present and future. Eur Respir J 2010; 36:225-8. [PMID: 20675775 DOI: 10.1183/09031936.00085510] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
36
|
Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J 2010; 37:806-12. [PMID: 20693248 DOI: 10.1183/09031936.00072510] [Citation(s) in RCA: 148] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Outcome measures to assess therapeutic interventions in cystic fibrosis (CF) patients with mild lung disease are lacking. Our aim was to determine if the lung clearance index (LCI) can detect a treatment response to dornase alfa in paediatric CF patients with normal spirometry. CF patients between 6-18 yrs of age with FEV(1 )≥ 80% pred were eligible. In a crossover design, 17 patients received 4 weeks of dornase alfa and placebo in a randomised sequence separated by a 4-week washout period. The primary end-point was the change in LCI from dornase alfa versus placebo. A mixed model approach incorporating period-dependent baselines was used. The mean ± sd age was 10.32 ± 3.35 yrs. Dornase alfa improved LCI versus placebo (0.90 ± 1.44; p = 0.022). Forced expiratory flow at 25-75% expired volume measured by % pred and z-scores also improved in subjects on dornase alfa (6.1% ± 10.34%; p = 0.03 and 0.28 ± 0.46 z-score; p = 0.03). Dornase alfa significantly improved LCI. Therefore the LCI may be a suitable tool to assess early intervention strategies in this patient population.
Collapse
Affiliation(s)
- R Amin
- Division of Respiratory Medicine, Dept of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Navratil T, Evans C, Schaberg A, Johnson F, Durham T, Ren C, Ratjen F, Moss R, Accurso F. Aerosol and pharmacokinetic properties of denufosol support its use for early intervention in CF lung disease. J Cyst Fibros 2010. [DOI: 10.1016/s1569-1993(10)60079-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
Abstract
The aim of this article is to describe the paediatric highlights from the 2009 European Respiratory Society Annual Congress in Vienna, Austria. The best abstracts from the seven groups of the Paediatric Assembly (asthma and allergy, respiratory epidemiology, cystic fibrosis, respiratory physiology, respiratory infections and immunology, neonatology and paediatric intensive care, and bronchology) are presented alongside findings from the current literature.
Collapse
Affiliation(s)
- P L P Brand
- Princess Amalia Children's Clinic, Isala Klinieken, Zwolle, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Barbato A, Bertuola F, Kuehni C, Korppi M, Kotecha S, Pijnenburg MW, Ratjen F, Seddon P, Bush A. Paediatrics in Berlin. Eur Respir J 2009; 34:436-43. [PMID: 19648520 DOI: 10.1183/09031936.00038809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The aim of this report is to describe the highlights of the European Respiratory Society annual congress in Berlin, Germany. The best abstracts in asthma and allergy, cystic fibrosis, respiratory infection, paediatric and neonatal intensive care, paediatric investigative techniques (in particular respiratory physiology and bronchoscopy) and respiratory epidemiology are presented and set in the context of the current literature.
Collapse
Affiliation(s)
- A Barbato
- Department of Paediatric, University of Padova, Padova, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Ratjen F, Munck A, Kho P, Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2009; 65:286-91. [DOI: 10.1136/thx.2009.121657] [Citation(s) in RCA: 225] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
41
|
Smyth AR, Barbato A, Beydon N, Bisgaard H, de Boeck K, Brand P, Bush A, Fauroux B, de Jongste J, Korppi M, O'Callaghan C, Pijnenburg M, Ratjen F, Southern K, Spencer D, Thomson A, Vyas H, Warris A, Merkus PJ. Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur Respir J 2009; 35:247-65. [PMID: 19840958 DOI: 10.1183/09031936.00139508] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
This European Respiratory Society task force has reviewed the evidence for paediatric medicines in respiratory disease occurring in adults and children. We describe off-licence use, research priorities and ongoing studies. Off-licence and off-label prescribing in children is widespread and potentially harmful. Research areas in asthma include novel formulations and regimens, and individualised prescribing. In cystic fibrosis, future studies will focus on screened infants and robust outcome measures are needed. Other areas include new enzyme and antibiotic formulations and the basic defect. Research into pneumonia should include evaluation of new antibacterials and regimens, rapid diagnostic tests and, in pleural infection, antibiotic penetration, fibrinolytics and surveillance. In uncommon conditions, such as primary ciliary dyskinesia, congenital pulmonary abnormalities or neuromuscular disorders, drugs indicated for other conditions (e.g. dornase alfa) are commonly used and trials are needed. In neuromuscular disorders, the beta-agonists may enhance muscle strength and are in need of evaluation. Studies of antibiotic prophylaxis, immunoglobulin and antifungal drugs are needed in immune deficiency. We hope that this summary of the evidence for respiratory medicines in children, highlighting gaps and research priorities, will be useful for the pharmaceutical industry, the paediatric committee of the European Medicines Agency, academic investigators and the lay public.
Collapse
Affiliation(s)
- A R Smyth
- University of Nottingham Division of Child Health, Queens Medical Centre, Nottingham, NG7 2UH, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Al-Saleh S, Mei-Zahav M, Faughnan ME, MacLusky IB, Carpenter S, Letarte M, Ratjen F. Screening for pulmonary and cerebral arteriovenous malformations in children with hereditary haemorrhagic telangiectasia. Eur Respir J 2009; 34:875-81. [DOI: 10.1183/09031936.00030009] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
43
|
Ratjen F. FROM BENCH TO BEDSIDE: MODULATION OF AIRWAY INFLAMMATION IN CYSTIC FIBROSIS. J Cyst Fibros 2008. [DOI: 10.1016/s1569-1993(08)60488-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
44
|
Eber E, Grasemann H, Thalhammer G, Widmann R, Ratjen F. Safety tolerability and efficacy of multiple doses of aerosolised Moli1901 in adolescents and adults with cystic fibrosis. J Cyst Fibros 2008. [DOI: 10.1016/s1569-1993(08)60087-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Abstract
Considerable advances in cystic fibrosis (CF) research have translated into improved patient care, reflected by a continuing trend of improving life expectancy in CF patients. This review summarises some of the major findings of CF research that have occurred in the past year. The review specifically focuses on those developments that have direct implications for patient care or those in which clinical trials suggest benefits that may impact on the treatment of CF patients in the near future.
Collapse
Affiliation(s)
- F Ratjen
- Hospital for Sick Children, Toronto, Ontario, Canada.
| |
Collapse
|
46
|
Corvol H, Boelle P, Brouard J, Knauer N, Henrion-Caude A, Chadelat K, Flamant C, Charlier C, Boule M, Fauroux B, Vallet C, Feingold J, Ratjen F, Grasemann H, Clement A. Cytokine polymorphisms influence lung disease progression in cystic fibrosis. J Cyst Fibros 2008. [DOI: 10.1016/s1569-1993(08)60012-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
47
|
Ratjen F, Stenglein S, Munck A. Inhaled tobramycin nebulizer solution for treatment of early Pseudomonas aeruginosa infection: the ELITE study. J Cyst Fibros 2008. [DOI: 10.1016/s1569-1993(08)60098-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
48
|
Grasemann C, Ratjen F, Schnabel D, Reutershahn E, Vester U, Grasemann H. Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. Eur Respir J 2008; 31:815-21. [DOI: 10.1183/09031936.00103907] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
49
|
Abstract
A 10-year-old girl developed recurrent bouts of massive hemoptysis over a 9-month period. No obvious bleeding source was detected. Her pulmonary angiogram showed a pulmonary aneurysm of the second branch of the left main pulmonary artery as well as widespread irregularities of the pulmonary arteries including areas of stenosis and pruning. Elective embolization of the aneurysm did not control hemoptysis and emergency left upper lobectomy had to be performed. Histology showed large artery wall injury with acute leucocytoclastic inflammation, fibrinoid necrosis, granulomatous inflammation, and ectasia of vessel wall. This combination of abnormalities has not been described to date and represents the first case of isolated pulmonary arteritis in children prior to puberty.
Collapse
Affiliation(s)
- E Y Chan
- Division of Respiratory Medicine, Hospital for Sick Children, Toronto, Ontario, Canada
| | | | | | | | | | | | | |
Collapse
|
50
|
Taylor L, Corey M, Matlow A, Sweezey NB, Ratjen F. Comparison of throat swabs and nasopharyngeal suction specimens in non-sputum-producing patients with cystic fibrosis. Pediatr Pulmonol 2006; 41:839-43. [PMID: 16850448 DOI: 10.1002/ppul.20451] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Both throat swabs and nasopharyngeal suction (NPS) specimens are used for microbiological assessment in non-sputum-producing patients with cystic fibrosis (CF), but studies comparing their diagnostic yield are lacking. We, therefore, conducted a prospective study in young CF patients, in which both techniques were performed in random order. Forty-seven consecutive CF children aged 6 months to 10 years were studied during routine visits to the clinic. CF relevant pathogens were found in the majority of patients with no significant differences in the rate of positive cultures for Staphylococcus aureus, Haemophilus influenzae, or Pseudomonas aeruginosa. A statistically significant difference was observed in the rate of detection of other organisms with only 9/47 (19%) of throat swab specimens and 27/47 (57%) of NPS specimens being positive (P = 0.0004). This included 12 positive cultures for Streptococcus pneumoniae and 11 cultures that were positive for Moraxella catarrhalis, both of which are frequent colonizers of the upper airway. Therefore, the most common bacterial pathogens affecting the CF lung appear to be detected in similar frequency by throat swab as by nasopharyngeal suction. There is evidence that nasopharyngeal suction yields more specimens of Streptococcus pneumoniae and Moraxella catarrhalis, which may reflect upper airway colonization rather than lower airway infection. We conclude that nasopharyngeal suction is not routinely warranted as there is no benefit over throat swab in detection of CF pathogens in infants and young children with CF.
Collapse
Affiliation(s)
- L Taylor
- Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, Canada
| | | | | | | | | |
Collapse
|